Radiopharmaceuticals Global Market is Projected to Reach $12.6 Billion by 2030: Innovative Radiopharmaceuticals to Boost Cardiac Applications

22 Jun 2023
Radiation Therapy
Dublin, June 21, 2023 /PRNewswire/ -- The "Radiopharmaceuticals: Global Strategic Business Report" report has been added to
ResearchAndMarkets.com's offering.
The global market for Radiopharmaceuticals estimated at US$6.3 Billion in the year 2022, is projected to reach a revised size of US$12.6 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2022-2030.
SPECT Radioisotopes, one of the segments analyzed in the report, is projected to record a 8.3% CAGR and reach US$5.4 Billion by the end of the analysis period.
Taking into account the ongoing post pandemic recovery, growth in the Pet Radioisotopes segment is readjusted to a revised 10% CAGR for the next 8-year period.
The U.S. Market is Estimated at $3 Billion, While China is Forecast to Grow at 11.5% CAGR
The Radiopharmaceuticals market in the U.S. is estimated at US$3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$836.1 Million by the year 2030 trailing a CAGR of 11.5% over the analysis period 2022 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 6.7% respectively over the 2022-2030 period.
Within Europe, Germany is forecast to grow at approximately 7.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$757.3 Million by the year 2030.
Select Competitors (Total 137 Featured) -
Ion Beam Applications S.A
Medi-Radiopharma Ltd
Novartis/Advanced Accelerator Applications
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of COVID-19 and a Looming Global Recession
2020: A Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021?
World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
Pandemic-Led Disruptions Affect Radiopharmaceuticals Supply, Hindering Nuclear Medicine Procedures in Several Countries
Imaging Screening Volume % Change 1H 2019 Vs 1H 2020 in US Hospitals
Distribution Bottlenecks amid COVID-19 Crisis Leave Hospitals Struggling with Supply of Medical Radioisotopes
Nuclear Medicine Services Limp Back to Normalcy after Easing of COVID-19 Restrictions
COVID-19 Presents Generational Opportunity
Radiopharmaceuticals - Global Key Competitors Percentage Market Share in 2022 (E)
Radiopharmaceuticals Competitor Market Share Scenario Worldwide (in %): 2020E
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
An Introduction to Radiopharmaceuticals
Mechanism of Action
Global Market Prospects & Outlook
Key Market Drivers
Market Restraints
Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
Classification of Radiopharmaceuticals
Diagnostic Radiopharmaceuticals: The Dominant Segment
Key Drivers
Positron Emission Tomography (PET)
Single Photon Emission Computed Tomography (SPECT)
Therapeutic Radiopharmaceuticals
Global Supply Shortages Continue to Challenge Market Growth
A Glimpse at Mo-99 Processors Worldwide
Nuclear Research Reactor Irradiators Worldwide: A Snapshot
Competitive Landscape
Radiopharmaceuticals Competitor Market Share Scenario Worldwide (in %): 2020
World Brands
Recent Industry Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Emergence of Radiotheranostics: Dual-Functioning Radiopharmaceuticals
Common Radionuclides Used in Theranostic Applications
Radiopharmaceuticals Become Promising for Cancer Theranostics
Changing Role of Radiopharmaceuticals in Diagnostic and Therapeutic Applications
Advent of New Radiopharmaceuticals Widen Scope
Select New Products
Startups Develop Unique Radiopharmaceutical Solutions
Potential Role of Carbon Dots in Imaging and Theranostics
Nano Radiopharmaceuticals: Promising Role in Therapeutic and Imaging Applications
Researchers Develop New Nanoparticles to Improve Radiopharmaceutical Efficiency
OncoinventOncoinvent and NPL Develops Unique Method to Measure & Deliver Dosages in Radiotherapy
Industry Focus Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits
Select Commercially Available Therapeutic Radiopharmaceuticals
Role of Radiopharmaceuticals as Diagnostic Technology
PET Eclipses SPECT in Cardiovascular Imaging
Worldwide Installed Base of Nuclear Imaging Equipment by Modality, PET Vs SPECT: 2020
Cardiac Amyloidosis Visualization: A Potential Application for PET
Innovative Radiopharmaceuticals to Boost Cardiac Applications
Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
Radiopharmaceuticals: Direct and Targeted Approach for Cancer Treatment
Rising Cancer Incidence Worldwide Spurs Demand
Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2020
Number of New Cancer Cases and Deaths (in Million) by Region for 2020
Intra-operative Lymphatic Mapping (ILM): Creates New Opportunities for Radiopharmaceuticals in Cancer Detection
Growing Prominence of Therapeutic Radiopharmaceuticals for Cancer Care
Rise in Incidence of Neurological Disorders to Drive Growth
Application of PET in Drug Development to Expand Opportunities
Personalized Medicine Drives Nuclear Medicine
Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population
Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019 and 2024
Gallium-68-labeled Radiopharmaceuticals: Production & Administering Challenges
Radiopharmaceuticals for COVID-19: Role in Diagnosis, Prognosis, and Therapeutic Uses
Arti?cial Intelligence: A Promising Tool in Radiotherapy and Radiopharmaceuticals
Aging Global Population: A Vital Demography
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Global Cancer Deaths by Age Group (in %) for 2019
Rise in Healthcare Expenditure to Drive Growth
World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021 & 2023
Elderly Healthcare Expenditure as a % of GDP in the US, Europe and Japan for 1970, 2010 and 2050
Relevant Aspects of Radiopharmaceutical Production
Regulatory Regime Governing Production and Use of Radiopharmaceuticals
The Facilitating Innovative Nuclear Diagnostics (FIND) Act, 2021
Challenges Facing Nuclear Medicine Industry
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/oyfnnz
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.